Imaging agent developer ImaginAb has formed a preclinical research collaboration with Eli Lilly to investigate potential T-cell-based immuno-oncology therapies.
Under the deal, ImaginAb will conduct preclinical research using its IAB22M2C immune imaging PET agent to detect T-cell trafficking, redirection, and infiltration in response to Lilly oncology molecules, according to the firms. ImaginAb will maintain full rights to its imaging agents used in the research project.
The companies did not disclose financial terms of the agreement.
